m6A甲基化修饰在膀胱癌中的作用

doi:10.16352/j.issn.1001-6325.2025.10.1372

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (10): 1372-1376.doi: 10.16352/j.issn.1001-6325.2025.10.1372

m6A甲基化修饰在膀胱癌中的作用

刘永辉¹, 武艳², 成波^3*

1.山东第二医科大学临床医学院,山东潍坊 261053;
2.滨州医学院附属医院医学研究中心山东滨州 256600;
3.东营胜利油田中心医院泌尿外科,山东东营 257099

收稿日期:2024-11-05 修回日期:2025-02-26 出版日期:2025-10-05 发布日期:2025-09-22
通讯作者: ^*edwardchengbo@126.com
基金资助:
国家自然科学基金(81903102)

Role of m6A methylation modification in bladder cancer

LIU Yonghui¹, WU Yan², CHENG Bo^3*

1. School of Clinical Medicine, Shandong Second Medical University, Weifang 261053;
2. Medical Research Center, Affiliated Hospital of Binzhou Medical College, Binzhou 256600;
3. Department of Urology, Shengli Oilfield Central Hospital, Dongying 257099, China

Received:2024-11-05 Revised:2025-02-26 Online:2025-10-05 Published:2025-09-22
Contact: ^*edwardchengbo@126.com

摘要/Abstract

摘要： N6甲基腺苷(m6A)甲基化修饰是一种常见的mRNA修饰形式,其参与调节mRNA的输出、剪接、翻译、定位和降解等,在基因的表达调控、机体的生长发育、肿瘤的发生发展等生理病理过程中发挥重要作用。膀胱癌中许多m6A甲基化相关分子的表达水平发生不同程度的改变,从而影响膀胱癌的临床治疗、预后等。m6A甲基化修饰与膀胱癌的发生发展密切相关,深入了解其相关调控机制有利于为m6A甲基化在膀胱癌的临床应用提供更多参考。

关键词: 膀胱癌, m6A甲基化修饰, 甲基转移酶, 去甲基化酶, 甲基化阅读器

Abstract: N6 methyladenosine(m6A) methylation modification is a common form of mRNA modification, which is involved in the regulation of mRNA output, splicing, translation, localization and degradation, and plays an important role in the regulation of gene expression, body growth and development, and the development of tumors. The expression levels of many m6A methylation-related molecules in bladder cancer are altered to varying degrees, thus affecting the clinical treatment and prognosis of bladder cancer. The m6A methylation modification is closely related to the occurrence and development of bladder cancer, and a deeper understanding of the relevant regulatory mechanisms is beneficial to provide more reference for the clinical application of m6A methylation in bladder cancer.

Key words: bladder cancer, m6A methylation modification, methyltransferase, demethylase, methylation reader

中图分类号:

R737.14

刘永辉, 武艳, 成波. m6A甲基化修饰在膀胱癌中的作用[J]. 基础医学与临床, 2025, 45(10): 1372-1376.

LIU Yonghui, WU Yan, CHENG Bo. Role of m6A methylation modification in bladder cancer[J]. Basic & Clinical Medicine, 2025, 45(10): 1372-1376.

参考文献

[1] Schwarzova L, Varchulova N Z, Danisovic L, et al. Molecular classification of urothelial bladder carcinoma[J]. Mol Biol Rep, 2023,50:7867-7877.
[2] Zhou Z, Zhang B, Deng Y, et al. FBW7/GSK3beta mediated degradation of IGF2BP2 inhibits IGF2BP2-SLC7A5 positive feedback loop and radioresistance in lung cancer[J]. J Exp Clin Cancer Res, 2024,43:34. doi:10.1186/s13046-024-02959-3.
[3] Sun L, Zhang Y, Yang B, et al. Lactylation of METTL16 promotes cuproptosis via m(6)A-modification on FDX1 mRNA in gastric cancer[J]. Nat Commun, 2023,14:6523.doi: 10.1038/s41467-023-42025-8.
[4] Oerum S, Meynier V, Catala M, et al. A comprehensive review of m6A/m6A/mRNA methyltransferase structures[J]. Nucleic Acids Res, 2021,49:7239-7255.
[5] Wang Y, Zhang L, Ren H, et al. Role of Hakai in m(6)A modification pathway in Drosophila[J]. Nat Commun, 2021,12:2159.doi: 10.1038/s41467-021-22424-5.
[6] Wen J, Lv R, Ma H, et al. Zc3h13 regulates nuclear RNA m(6)A methylation and mouse embryonic stem cell self-renewal[J]. Mol Cell, 2018,69:1028-1038.
[7] Xu C, Liu K, Tempel W, et al. Structures of human ALKBH5 demethylase reveal a unique binding mode for specific single-stranded N6-methyladenosine RNA demethylation[J]. J Biol Chem, 2014,289:17299-17311.
[8] Zhou C, She X, Gu C, et al. FTO fuels diabetes-induced vascular endothelial dysfunction associated with inflammation by erasing m6A methylation of TNIP1[J]. J Clin Invest, 2023,133.doi: 10.1172/JCI160517.
[9] Chen L, Gao Y, Xu S, et al. N6-methyladenosine reader YTHDF family in biological processes: Structures, roles, and mechanisms[J]. Front Immunol, 2023,14:1162607.doi: 10.3389/fimmu.2023.
[10] Zou Z, He C. The YTHDF proteins display distinct cellular functions on m(6)A-modified RNA[J]. Trends Biochem Sci, 2024,49:611-621.
[11] Muller S, Glass M, Singh A K, et al. IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner[J]. Nucleic Acids Res, 2019,47:375-390.
[12] Zhang H, Wu D, Wang Y, et al. METTL3-mediated N6-methyladenosine exacerbates ferroptosis via m6A-IGF2BP2-dependent mitochondrial metabolic reprogram-ming in sepsis-induced acute lung injury[J]. Clin Transl Med, 2023,13:e1389.doi: 10.1002/ctm2.1389.
[13] Lin Z, Li J, Zhang J, et al. Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR inhibitors in non-small cell lung cancer[J]. Cancer Res, 2023,83:2187-2207.
[14] Zhang L, Li Y, Zhou L, et al. The m6A reader YTHDF2 promotes bladder cancer progression by suppressing RIG-I-mediated immune response[J]. Cancer Res, 2023,83:1834-1850.
[15] Tao L, Mu X, Chen H, et al. FTO modifies the m6A level of MALAT and promotes bladder cancer progression[J]. Clin Transl Med, 2021,11:e310.doi: 10.1002/ctm2.310.
[16] Song W, Yang K, Luo J, et al. Dysregulation of USP18/FTO/PYCR1 signaling network promotes bladder cancer development and progression[J]. Aging (Albany NY), 2021,13:3909-3925.
[17] Kong J, Lu S, Zhang L, et al. m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent[J]. Front Immunol, 2022,13:1014861.doi: 10.3389/fimmu.2022.1014861.
[18] Mao X, Chen X, Xu Z, et al. The identification of a N(6)-methyladenosin-modifed immune pattern to predict immunotherapy response and survival in urothelial carcinoma[J]. Aging (Albany NY), 2024,16:7774-7798.
[19] Zheng B, Wang J, Zhao G, et al. A new m6A methylation-related gene signature for prognostic value in patient with urothelial carcinoma of the bladder[J]. Biosci Rep, 2021,41:BSR20204456.doi: 10.1042/BSR20204456.
[20] Wang X, Yu J, Chen J, et al. Copy number variation analysis of m(6) A regulators identified METTL3 as a prognostic and immune-related biomarker in bladder cancer[J]. Cancer Med, 2021,10:7804-7815.
[21] Yang L, Ying J, Tao Q, et al. RNA N(6)-methyladenosine modifications in urological cancers: from mech-anism to application[J]. Nat Rev Urol, 2024,21:460-476.
[22] Wei Z, Chen Y, Zeng Z, et al. The novel m6A writer METTL5 as prognostic biomarker probably associating with the regulation of immune microenvironment in kidney cancer[J]. Heliyon, 2022,8:e12078.doi: 10.1016/j.heliyon.
[23] Wang B, Jiang J, Luo D, et al. Pan-cancer analysis reveals potential immunological and prognostic roles of METTL7A in human cancers[J]. Sci Rep, 2024,14:3476.doi: 10.1038/s41598-024-54255-x.
[24] Pierconti F, Rossi ED, Cenci T, et al. DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group[J]. Cancer Cytopathol, 2023,131:158-164.

m6A甲基化修饰在膀胱癌中的作用

Role of m6A methylation modification in bladder cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	付淼, 刘蓬, 田文, 王莎, 尹晓梅, 刘昊, 王东海. METTL3通过介导TRPM7甲基化调节宫颈癌细胞铁死亡和恶性进展[J]. 基础医学与临床, 2025, 45(10): 1318-1325.
[2]	梁宇, 李俊虹, 王建琼, 魏丽, 蒋杰, 王明圆, 苏敏. 下调METTL3降低Hcy诱导的巨噬细胞M1极化和泡沫化[J]. 基础医学与临床, 2025, 45(10): 1341-1349.
[3]	周昌东, 林洋, 孙凯, 田玉新. 敲降lncRNA UCA1降低人膀胱癌细胞系T24对吉西他滨耐药[J]. 基础医学与临床, 2024, 44(8): 1113-1119.
[4]	卢慧莹, 王建国. 下调去甲基化酶FTO抑制人肝癌细胞系HepG2增殖[J]. 基础医学与临床, 2024, 44(2): 185-191.
[5]	杨琳, 曲智, 王源, 易文学, 辛锦, 尹小暖, 段东晓. m⁶A甲基转移酶样蛋白14在抑郁样小鼠海马中的表达[J]. 基础医学与临床, 2024, 44(10): 1376-1382.
[6]	陈辛, 陈俊, 徐幸, 王旭. 组蛋白去甲基化酶抑制剂GSK-J4减轻高脂诱导的肥胖小鼠体质量[J]. 基础医学与临床, 2023, 43(9): 1353-1358.
[7]	张培波, 李义. 沙棘总黄酮抑制膀胱癌细胞系T24增殖[J]. 基础医学与临床, 2023, 43(7): 1122-1126.
[8]	邹瑾, 何向蕾, 张欣, 陈日萍, 张宇, 胡帅悦, 应士波. 蛋白质精氨酸残基化学修饰酶PADs与PRMTs在人肝癌细胞系中的表达[J]. 基础医学与临床, 2023, 43(6): 898-903.
[9]	闫军, 冯永安, 石永奎, 赵志浩, 倪怀亮, 杨维桢. 桔梗皂苷D增强人直肠癌耐药细胞株SW1463/Oxa对奥沙利铂的敏感性[J]. 基础医学与临床, 2023, 43(4): 603-607.
[10]	田平平, 宁洁, 邹琴, 卢雨微, 郭兵, 石明隽. 5-氮杂-2’-脱氧胞苷对高糖培养的NRK-52E细胞中分泌型卷曲相关蛋白1表达的影响[J]. 基础医学与临床, 2022, 42(8): 1194-1199.
[11]	白冰, 张海芳, 杨庆良, 秦悦, 周晨龙, 宋歌, 王颖. 下调lncRNA RHPN1-AS1抑制人膀胱癌细胞系T24增殖和迁移[J]. 基础医学与临床, 2022, 42(6): 940-944.
[12]	杨芒庄, 杨旭东, 王晓龙. Circ-MALAT1靶向miR-101抑制膀胱癌细胞系SW780侵袭和迁移[J]. 基础医学与临床, 2022, 42(3): 472-478.
[13]	徐林飞, 张海涛, 刘晟, 蔡海荣, 胡恩平. 白花蛇舌草上调miR-485-5p抑制人膀胱癌细胞系KU-19-19增殖、迁移和侵袭[J]. 基础医学与临床, 2021, 41(6): 842-847.
[14]	方黄毅, 尤朝国, 庞晨, 章钟鼎, 张哲, 况统帅, 盛汉松. FM19G11体外增敏替莫唑胺对MGMT阳性恶性胶质瘤细胞系的作用机制[J]. 基础医学与临床, 2021, 41(4): 514-520.
[15]	杨锋, 徐佳, 仇国辉, 杨志玲. miR-491-5p参与调节人膀胱癌细胞系EJ对5-氟尿嘧啶的敏感性[J]. 基础医学与临床, 2021, 41(2): 233-239.